• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于循环湿式搅拌介质磨中药物纳米研磨的新型过程强化方法:批次大小、流速和返混的影响

A Novel PBM for Nanomilling of Drugs in a Recirculating Wet Stirred Media Mill: Impacts of Batch Size, Flow Rate, and Back-Mixing.

作者信息

Heidari Hamidreza, Muanpaopong Nontawat, Guner Gulenay, Yao Helen F, Clancy Donald J, Bilgili Ecevit

机构信息

Otto H. York Department of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.

Drug Product Development, GlaxoSmithKline, Collegeville, PA 19426, USA.

出版信息

Pharmaceutics. 2024 Mar 2;16(3):353. doi: 10.3390/pharmaceutics16030353.

DOI:10.3390/pharmaceutics16030353
PMID:38543247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10974007/
Abstract

We examined the evolution of fenofibrate (FNB, drug) particle size distribution (PSD) during the production of nanosuspensions via wet stirred media milling (WSMM) with a cell-based population balance model (PBM). Our objective was to elucidate the potential impacts of batch size, suspension volumetric flow rate, and imperfect mixing in a recirculating WSMM. Various specific breakage rate functions were fitted to experimental PSD data at baseline conditions assuming perfect mixing. Then, the best function was used to simulate the PSD evolution at various batch sizes and flow rates to validate the model. A novel function, which is a product of power-law and logistic functions, fitted the evolution the best, signifying the existence of a transition particle size commensurate with a grinding limit. Although larger batches yielded coarser and wider PSDs, the suspensions had identical PSDs when milled for the same effective milling time. The flow rate had an insignificant influence on the PSD. Furthermore, the imperfect mixing in the mill chamber was simulated by considering more than one cell and different back-mixing flow ratios. The effects were weak and restricted to the first few turnovers. These insights contribute to our understanding of recirculating WSMM, providing valuable guidance for process development.

摘要

我们使用基于细胞的总体平衡模型(PBM),通过湿式搅拌介质研磨(WSMM)研究了非诺贝特(FNB,药物)纳米悬浮液生产过程中粒径分布(PSD)的演变。我们的目的是阐明批量大小、悬浮液体积流速以及循环式WSMM中混合不充分的潜在影响。在假设完全混合的基线条件下,将各种特定破碎速率函数拟合到实验PSD数据。然后,使用最佳函数模拟不同批量大小和流速下的PSD演变,以验证模型。一种由幂律函数和逻辑函数相乘得到的新函数对演变的拟合效果最佳,这表明存在与研磨极限相对应的转变粒径。尽管较大的批次会产生更粗且更宽的PSD,但当研磨相同的有效研磨时间时,悬浮液具有相同的PSD。流速对PSD的影响不显著。此外,通过考虑多个单元和不同的返混流率来模拟研磨室内的混合不充分情况。影响较弱且仅限于最初的几个周转。这些见解有助于我们理解循环式WSMM,为工艺开发提供有价值的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/d15a8d963bdb/pharmaceutics-16-00353-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/52ca4052e795/pharmaceutics-16-00353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/0a17f4187de2/pharmaceutics-16-00353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/ceb3b8bf7cce/pharmaceutics-16-00353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/583926f0e12f/pharmaceutics-16-00353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/466b9f20bff8/pharmaceutics-16-00353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/59a9837a1cff/pharmaceutics-16-00353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/e100bae5d1ff/pharmaceutics-16-00353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/95837c000fe7/pharmaceutics-16-00353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/9e21344c3513/pharmaceutics-16-00353-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/80572315e22c/pharmaceutics-16-00353-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/015a5f566276/pharmaceutics-16-00353-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/a97741d33d28/pharmaceutics-16-00353-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/d0c6612edd09/pharmaceutics-16-00353-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/1dac3991d0a4/pharmaceutics-16-00353-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/1b40e0577a17/pharmaceutics-16-00353-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/185fd8a4592f/pharmaceutics-16-00353-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/d15a8d963bdb/pharmaceutics-16-00353-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/52ca4052e795/pharmaceutics-16-00353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/0a17f4187de2/pharmaceutics-16-00353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/ceb3b8bf7cce/pharmaceutics-16-00353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/583926f0e12f/pharmaceutics-16-00353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/466b9f20bff8/pharmaceutics-16-00353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/59a9837a1cff/pharmaceutics-16-00353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/e100bae5d1ff/pharmaceutics-16-00353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/95837c000fe7/pharmaceutics-16-00353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/9e21344c3513/pharmaceutics-16-00353-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/80572315e22c/pharmaceutics-16-00353-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/015a5f566276/pharmaceutics-16-00353-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/a97741d33d28/pharmaceutics-16-00353-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/d0c6612edd09/pharmaceutics-16-00353-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/1dac3991d0a4/pharmaceutics-16-00353-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/1b40e0577a17/pharmaceutics-16-00353-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/185fd8a4592f/pharmaceutics-16-00353-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc3/10974007/d15a8d963bdb/pharmaceutics-16-00353-g017.jpg

相似文献

1
A Novel PBM for Nanomilling of Drugs in a Recirculating Wet Stirred Media Mill: Impacts of Batch Size, Flow Rate, and Back-Mixing.一种用于循环湿式搅拌介质磨中药物纳米研磨的新型过程强化方法:批次大小、流速和返混的影响
Pharmaceutics. 2024 Mar 2;16(3):353. doi: 10.3390/pharmaceutics16030353.
2
Analysis of heat generation during the production of drug nanosuspensions in a wet stirred media mill.湿磨搅拌介质中制备药物纳米混悬剂过程中的发热分析。
Int J Pharm. 2022 Aug 25;624:122020. doi: 10.1016/j.ijpharm.2022.122020. Epub 2022 Jul 14.
3
Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the Rehbinder effect.通过湿搅拌介质研磨连续生产药物纳米颗粒悬浮液:重新审视雷宾德效应。
Drug Dev Ind Pharm. 2013 Feb;39(2):266-83. doi: 10.3109/03639045.2012.676048. Epub 2012 Apr 16.
4
Use of Bead Mixtures as a Novel Process Optimization Approach to Nanomilling of Drug Suspensions.使用珠粒混合物作为一种新颖的纳米悬浮液药物处理过程优化方法。
Pharm Res. 2021 Jul;38(7):1279-1296. doi: 10.1007/s11095-021-03064-2. Epub 2021 Jun 24.
5
Mechanistic Modeling of Wet Stirred Media Milling for Production of Drug Nanosuspensions.湿磨搅拌介质法制备药物纳米混悬剂的机理建模。
AAPS PharmSciTech. 2020 Nov 22;22(1):2. doi: 10.1208/s12249-020-01876-w.
6
Kinetic and Microhydrodynamic Modeling of Fenofibrate Nanosuspension Production in a Wet Stirred Media Mill.在湿式搅拌介质磨中制备非诺贝特纳米混悬液的动力学和微流体动力学建模
Pharmaceutics. 2021 Jul 10;13(7):1055. doi: 10.3390/pharmaceutics13071055.
7
Do Mixtures of Beads with Different Sizes Improve Wet Stirred Media Milling of Drug Suspensions?不同尺寸珠子的混合物能否改善药物悬浮液的湿式搅拌介质研磨?
Pharmaceutics. 2023 Aug 26;15(9):2213. doi: 10.3390/pharmaceutics15092213.
8
Scale-up from batch to flow-through wet milling process for injectable depot formulation.从批量到连续流湿法研磨工艺扩大用于注射用长效制剂的生产规模。
Eur J Pharm Sci. 2016 Dec 1;95:122-129. doi: 10.1016/j.ejps.2016.08.043. Epub 2016 Aug 26.
9
An Enthalpy-Balance Model for Timewise Evolution of Temperature during Wet Stirred Media Milling of Drug Suspensions.药物混悬液湿搅拌介质研磨过程中温度随时间演变的焓平衡模型。
Pharm Res. 2022 Sep;39(9):2065-2082. doi: 10.1007/s11095-022-03346-3. Epub 2022 Aug 2.
10
Preparation of fenofibrate nanoparticles by combined stirred media milling and ultrasonication method.采用搅拌介质研磨与超声联合法制备非诺贝特纳米粒。
Ultrason Sonochem. 2014 May;21(3):1100-7. doi: 10.1016/j.ultsonch.2013.12.001. Epub 2013 Dec 12.

本文引用的文献

1
Kinetic and Microhydrodynamic Modeling of Fenofibrate Nanosuspension Production in a Wet Stirred Media Mill.在湿式搅拌介质磨中制备非诺贝特纳米混悬液的动力学和微流体动力学建模
Pharmaceutics. 2021 Jul 10;13(7):1055. doi: 10.3390/pharmaceutics13071055.
2
Mechanistic Modeling of Wet Stirred Media Milling for Production of Drug Nanosuspensions.湿磨搅拌介质法制备药物纳米混悬剂的机理建模。
AAPS PharmSciTech. 2020 Nov 22;22(1):2. doi: 10.1208/s12249-020-01876-w.
3
Impact of media material and process parameters on breakage kinetics-energy consumption during wet media milling of drugs.
在药物湿磨过程中,介质材料和工艺参数对破损动力学和能量消耗的影响。
Eur J Pharm Biopharm. 2020 Aug;153:52-67. doi: 10.1016/j.ejpb.2020.05.024. Epub 2020 Jun 6.
4
Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques.湿法制粒技术制备药物纳米晶体的设计空间与质量源于设计方法
Pharmaceutics. 2018 Jul 25;10(3):104. doi: 10.3390/pharmaceutics10030104.
5
Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation⁻Processing Aspects and Challenges.通过纳米复合材料提高难溶性药物的生物利用度:制剂-工艺方面及挑战
Pharmaceutics. 2018 Jul 8;10(3):86. doi: 10.3390/pharmaceutics10030086.
6
Pharmaceutical nanocrystals: production by wet milling and applications.药物纳米晶体:湿磨法生产及应用。
Drug Discov Today. 2018 Mar;23(3):534-547. doi: 10.1016/j.drudis.2018.01.016. Epub 2018 Jan 8.
7
A microhydrodynamic rationale for selection of bead size in preparation of drug nanosuspensions via wet stirred media milling.通过湿式搅拌介质研磨制备药物纳米混悬液时选择珠粒尺寸的微流体动力学原理。
Int J Pharm. 2017 May 30;524(1-2):178-192. doi: 10.1016/j.ijpharm.2017.04.001. Epub 2017 Apr 2.
8
New Approach and Practical Modelling of Bead Milling Process for the Manufacturing of Nanocrystalline Suspensions.用于制造纳米晶体悬浮液的珠磨工艺的新方法及实用建模
J Pharm Sci. 2017 Jul;106(7):1889-1904. doi: 10.1016/j.xphs.2017.02.036. Epub 2017 Mar 14.
9
Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability.药物纳米晶体的稳定剂:对生物利用度的影响
Pharmaceutics. 2016 May 20;8(2):16. doi: 10.3390/pharmaceutics8020016.
10
Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.用于提高生物利用度的药物纳米研磨:整体制剂 - 工艺视角
Pharmaceutics. 2016 May 20;8(2):17. doi: 10.3390/pharmaceutics8020017.